Mechanism of Action
Thymic Epithelial Cell Stimulation
Vilon is proposed to interact with thymic stromal cells and epithelial cells, stimulating production of thymulin and other thymic factors that guide T-lymphocyte maturation. In cell culture studies, it promotes differentiation of lymphoid progenitors and enhances expression of thymosin, thymulin, and thymic humoral factor. This nominally reverses functional thymic involution.
Epigenetic Regulation
Khavinson's group has proposed that short peptide bioregulators including vilon interact with cell type-specific promoter regions in the genome, acting as gene expression modulators. Vilon specifically appears to increase expression of genes involved in lymphopoiesis when applied to thymic cell cultures. This epigenetic mechanism, if validated, would explain tissue-specific effects of dipeptides.
Research Summary
Animal Longevity
Limited EvidenceRat studies: vilon treatment extended mean lifespan by 15-20% and reduced tumor incidence compared to untreated controls. Immune parameters (T-cell numbers, NK activity) were better preserved in aging vilon-treated animals. Results are from single research group and have not been independently replicated in Western systems.
Human Immune Restoration
Limited EvidenceSmall series of elderly subjects (60-80 years) showed increases in CD3+ T-cells, improvements in lymphocyte response to mitogens, and normalized CD4/CD8 ratios after 10-day vilon courses. These observational findings align with the proposed thymic restoration mechanism but lack placebo-controlled trial validation.
Calculate your Vilon dose Vial strength, BAC water, exact syringe draw in IU. Free, no signup. Open Calc →
Research Protocols
| Goal | Dose | Frequency | Route |
|---|---|---|---|
| Immune restoration / bioregulation | 100-200 mcg SC daily for 10 days | Daily x10 days | Subcutaneous |
| Longevity maintenance | 100 mcg/day SC for 10 days, repeated 2-4x per year | Seasonal courses | Subcutaneous |
Often combined with Epitalon in Khavinson protocol literature. Minimal human pharmacokinetic data available.
Interactions
Safety Profile
No significant adverse effects reported in published series. Being a simple dipeptide of two common amino acids (lysine and glutamic acid), it is unlikely to produce direct toxicity. Short half-life limits systemic accumulation. Theoretical concerns include immune overstimulation in autoimmune-prone individuals. The absence of Western-standard clinical trials means the full safety profile cannot be formally characterized. Most reported human experience involves short 10-day courses with favorable tolerability.
References
- [1]Khavinson VKh, et al. Lys-Glu dipeptide restores immune function and increases life span. Bull Exp Biol Med. 2002;133(6):558-560.
- [2]Khavinson VKh. Peptides and ageing. Neuro Endocrinol Lett. 2002;23(Suppl 3):11-144.